Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCoca-cola Euro. Regulatory News (CCEP)

Share Price Information for Coca-cola Euro. (CCEP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 67.80
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 1.60 (2.388%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 67.80
CCEP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

CCEP receives FIRB approval to acquire CCL

1 Feb 2021 07:00

RNS Number : 4585N
Coca-Cola European Partners plc
01 February 2021
 

 

1 February 2021

 

Coca-Cola European Partners (CCEP) today confirms receipt of regulatory approval fromthe Australian Foreign Investment Review Board (FIRB)to acquire Coca-Cola Amatil Limited (CCL)

 

· As CCEP progresses further with the acquisition of CCL, CCEP today provides an update on the status of regulatory approvals relating to the transaction

 

· The Scheme implementation deed between CCEP and CCL is subject to regulatory approval from both the FIRB and the New Zealand Overseas Investment Office (OIO)

 

· CCEP today confirms receipt of the FIRB approval, dated 29 January 2021

 

· The Scheme remains subject to other customary conditions, including CCL independent shareholder approval, court approval and the OIO regulatory approval. Further updates will be provided in due course

 

For further information on the transaction, please see on our website:

Latest release (4 November 2020)

https://ir.cocacolaep.com/regulatory-filings-and-news/investor-news/investor-news-details/2020/Coca-Cola-Euro-Ptnrs---Update-re-Coca-Cola-Amatil-acquisition/default.aspx 

Analyst & investor presentation (25 October 2020)

https://s24.q4cdn.com/897379916/files/doc_presentations/2020/11/CCEP.-Proposed-acquisition-of-Coca-Cola-Amatil-Q3-Update.pdf

 

Advisers

Rothschild & Co are acting as lead financial adviser and Credit Suisse are acting as financial adviser to the Affiliated Transaction Committee (ATC) of the Board of Directors of CCEP. Slaughter and May and Corrs Chambers Westgarth are acting as legal counsel to CCEP.

 

Enquiries

Clare Wardle, General Counsel and Company Secretary: secretariat@ccep.com 

Investor Relations: Sarah Willett: sarah.willett@ccep.com +44 7970 145 218

Media:

Shanna Wendt: swendt@ccep.com +44 7976 595 168

Peter Brookes: pbrookes@citadelmagnus.com +61 407 911 389

Brett Clegg:  bclegg@citadelmagnus.com +61 487 436 985

 

About CCEP (LEI 549300LTH67W4GWMRF57)

Coca-Cola European Partners plc is a leading consumer goods company in Western Europe, making, selling & distributing an extensive range of non-alcoholic ready to drink beverages & is the world's largest Coke bottler based on revenue. CCEP serves a consumer population of over 300 million across Western Europe, including Andorra, Belgium, continental France, Germany, Great Britain, Iceland, Luxembourg, Monaco, the Netherlands, Norway, Portugal, Spain & Sweden. The Company is listed on Euronext Amsterdam, the New York Stock Exchange, London Stock Exchange & on the Spanish Stock Exchanges, trading under the symbol CCEP. For more information about CCEP, please visit www.cocacolaep.com & follow CCEP on Twitter at @CCEP.

 

About CCL

Coca-Cola Amatil Limited (including subsidiaries, group entities and related bodies corporate) is one of the largest bottlers and distributors of ready-to-drink non-alcohol and alcohol beverages and coffee in the Asia Pacific region. CCL is the authorised bottler and distributor of KO's beverage brands in Australia, New Zealand, Fiji, Indonesia, Papua New Guinea and Samoa. CCL directly employs around 12,000 people and indirectly creates thousands more jobs across the supply chain, partnering with key suppliers to bottle, package, sell and distribute its products. With access to around 270 million potential consumers through more than 630,000 active customers CCL is committed to leading through innovation, building a sustainable future and delivering long-term value, both to shareholders and to society. For more information, visit www.ccamatil.com 

 

No incorporation of website information

The content of the websites referred to in this announcement is not incorporated into and does not form part of this announcement.

 

 

End

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACQDKDBPCBKDNDN
Date   Source Headline
1st Sep 20223:00 pmRNSTotal Voting Rights
22nd Aug 20224:00 pmRNSDirector/PDMR Shareholding
4th Aug 20227:00 amRNSResults for the six months ended 1 July 2022
2nd Aug 20224:35 pmRNSPrice Monitoring Extension
1st Aug 20223:45 pmRNSTotal Voting Rights
20th Jul 20224:30 pmRNSDirector/PDMR Shareholding
14th Jul 20223:15 pmRNSDirector/PDMR Shareholding
23rd Jun 202212:30 pmRNSDirector/PDMR Shareholding
9th Jun 202212:00 pmRNSDirector/PDMR Shareholding
1st Jun 20223:10 pmRNSTotal Voting Rights
27th May 20223:30 pmRNSResult of AGM
24th May 20223:30 pmRNSDirector/PDMR Shareholding
16th May 202212:00 pmRNSLetter to Shareholders
3rd May 20222:40 pmRNSTotal Voting Rights
28th Apr 20224:41 pmRNSSecond Price Monitoring Extn
28th Apr 20224:36 pmRNSPrice Monitoring Extension
27th Apr 20227:00 amRNSQ1 2022 Trading Update
21st Apr 20225:20 pmRNSDirector/PDMR Shareholding
14th Apr 20229:00 amRNSNotice of AGM
23rd Mar 20221:50 pmRNSDirector/PDMR Shareholding
18th Mar 20222:15 pmRNSBlock listing Interim Review
17th Mar 20225:30 pmRNSDirector/PDMR Shareholding
15th Mar 20226:11 pmRNSAnnual Financial Report
14th Mar 20226:30 pmRNSDirector/PDMR Shareholding
10th Mar 20226:00 pmRNSDirector/PDMR Shareholding
9th Mar 20229:06 amRNSDirector/PDMR Shareholding
8th Mar 20224:00 pmRNSDirector/PDMR Shareholding
4th Mar 20224:00 pmRNSDirector/PDMR Shareholding
1st Mar 20222:00 pmRNSTotal Voting Rights
28th Feb 20225:30 pmRNSDirector/PDMR Shareholding
23rd Feb 20225:30 pmRNSDirector/PDMR Shareholding
16th Feb 20224:35 pmRNSPrice Monitoring Extension
16th Feb 20227:00 amRNSPreliminary Unaudited Results Q4 & FY 2021
1st Feb 20221:30 pmRNSTotal Voting Rights
24th Jan 20223:00 pmRNSDirector/PDMR Shareholding
4th Jan 202212:45 pmRNSTotal Voting Rights
21st Dec 20213:45 pmRNSDirector/PDMR Shareholding
16th Dec 20211:45 pmRNSDirector/PDMR Shareholding
1st Dec 20212:45 pmRNSTotal Voting Rights
23rd Nov 20213:15 pmRNSDirector/PDMR Shareholding
17th Nov 20214:35 pmRNSPrice Monitoring Extension
9th Nov 20217:00 amRNSQ3 Trading Update & FY21 Dividend Declaration
1st Nov 20212:30 pmRNSTotal Voting Rights
25th Oct 20214:41 pmRNSSecond Price Monitoring Extn
25th Oct 20214:36 pmRNSPrice Monitoring Extension
21st Oct 20214:41 pmRNSSecond Price Monitoring Extn
21st Oct 20214:36 pmRNSPrice Monitoring Extension
20th Oct 20214:40 pmRNSSecond Price Monitoring Extn
20th Oct 20214:35 pmRNSPrice Monitoring Extension
20th Oct 20214:30 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.